<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Res Med Sci</journal-id><journal-id journal-id-type="iso-abbrev">J Res Med Sci</journal-id><journal-id journal-id-type="publisher-id">JRMS</journal-id><journal-title-group><journal-title>Journal of Research in Medical Sciences : The Official Journal of Isfahan University of Medical Sciences</journal-title></journal-title-group><issn pub-type="ppub">1735-1995</issn><issn pub-type="epub">1735-7136</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25767516</article-id><article-id pub-id-type="pmc">4354059</article-id><article-id pub-id-type="publisher-id">JRMS-20-13</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title><italic>Pimpinella anisum</italic> in the treatment of functional dyspepsia: A double-blind, randomized clinical trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ghoshegir</surname><given-names>S. Ashraffodin</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mazaheri</surname><given-names>Mohammad</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Ghannadi</surname><given-names>Alireza</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Feizi</surname><given-names>Awat</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Babaeian</surname><given-names>Mahmoud</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Tanhaee</surname><given-names>Maryam</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Karimi</surname><given-names>Mehrdad</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Adibi</surname><given-names>Peyman</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Iranian Traditional Medicine, School of Medicine, Iran University of Medical Sciences, Tehran, Iran</aff><aff id="aff2"><label>2</label>Department of Iranian Traditional Medicine, Isfahan University of Medical Sciences, Isfahan, Iran</aff><aff id="aff3"><label>3</label>Department of Pharmacognosy, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran</aff><aff id="aff4"><label>4</label>Department of Biostatistics and Epidemiology, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran</aff><aff id="aff5"><label>5</label>Department of Iranian Traditional Medicine, Faculty of Medicine, Shahed University, Tehran, Iran</aff><aff id="aff6"><label>6</label>Department of Iranian Traditional Medicine School, Tehran University of Medical Science, Tehran, Iran</aff><aff id="aff7"><label>7</label>Integrative Functional Gastroenterology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran</aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Dr. Mohammad Mazaheri, Department of Iranian Traditional Medicine, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. E-mail: <email xlink:href="mazaherimohammad@yahoo.com">mazaherimohammad@yahoo.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>1</month><year>2015</year></pub-date><volume>20</volume><issue>1</issue><fpage>13</fpage><lpage>21</lpage><history><date date-type="received"><day>12</day><month>6</month><year>2014</year></date><date date-type="rev-recd"><day>16</day><month>7</month><year>2014</year></date><date date-type="accepted"><day>21</day><month>7</month><year>2014</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Journal of Research in Medical Sciences</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title>Background:</title><p>We aimed to evaluate the effects of <italic>Pimpinella anisum</italic> (anise) from Apiaceae family on relieving the symptoms of postprandial distress syndrome (PDS) in this double-blind randomized clinical trial.</p></sec><sec id="st2"><title>Materials and Methods:</title><p>Totally, 107 patients attending the gastroenterology clinic, aged 18-65 years, diagnosed with PDS according to ROME III criteria and signed a written consent form were enrolled. They were randomized to receive either anise or placebo, blindly, for 4 weeks. Anise group included 47 patients and received anise powders, 3 g after each meal (3 times/day). Control group involved 60 patients and received placebo powders (corn starch), 3 gafter each meal (3 times/day). The severity of Functional dyspepsia (FD) symptoms was assessed by FD severity scale. Assessments were done at baseline and by the end of weeks 2, 4 and 12. Mean scores of severity of FD symptoms and the frequency distribution of patients across the study period were compared.</p></sec><sec id="st3"><title>Results:</title><p>The age, sex, body mass index, smoking history, and coffee drinking pattern of the intervention and control groups were not significantly different. Mean (standard deviation) total scores of FD severity scale before intervention in the anise and control groups were 10.6 (4.1) and 10.96 (4.1), respectively (<italic>P</italic> = 0.6). They were 7.04 (4.1) and 12.30 (4.3) by week 2, respectively (<italic>P</italic> = 0.0001), 2.44 (4.2) and 13.05 (5.2) by week 4, respectively (<italic>P</italic> = 0.0001), and 1.08 (3.8) and 13.30 (6.2) by week 12, respectively (<italic>P</italic> = 0.0001).</p></sec><sec id="st4"><title>Conclusion:</title><p>This study showed the effectiveness of anise in relieving the symptoms of postpartum depression. The findings were consistent across the study period at weeks 2, 4 and 12.</p></sec></abstract><kwd-group><kwd>Anise</kwd><kwd>functional dyspepsia</kwd><kwd><italic>Pimpinella anisum</italic></kwd><kwd>postprandial distress syndrome</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>INTRODUCTION</title><p>Functional dyspepsia (FD) is a prevalent gastrointestinal (GI) disorder. Its prevalence is different in various populations and outpatient clinics.[<xref rid="ref1" ref-type="bibr">1</xref>] The patients suffer from dyspepsia, but no pathologic lesion, or metabolic abnormality is identified.[<xref rid="ref2" ref-type="bibr">2</xref>] They complain about epigastric pain/burning or upper abdomen postprandial discomforts. According to Rome III criteria, FD includes two main subtypes of epigastric pain syndrome and postprandial distress syndrome (PDS).[<xref rid="ref3" ref-type="bibr">3</xref><xref rid="ref4" ref-type="bibr">4</xref>] The latter involves patients with meal-related symptoms of bothersome postprandial fullness and early satiety. Its etiology is very complex and may include gastric dysmotility (delayed gastric emptying),[<xref rid="ref5" ref-type="bibr">5</xref><xref rid="ref6" ref-type="bibr">6</xref><xref rid="ref7" ref-type="bibr">7</xref>] <italic>Helicobacter pylori</italic> infection,[<xref rid="ref8" ref-type="bibr">8</xref><xref rid="ref9" ref-type="bibr">9</xref><xref rid="ref10" ref-type="bibr">10</xref><xref rid="ref11" ref-type="bibr">11</xref><xref rid="ref12" ref-type="bibr">12</xref>] local inflammations,[<xref rid="ref2" ref-type="bibr">2</xref><xref rid="ref13" ref-type="bibr">13</xref><xref rid="ref14" ref-type="bibr">14</xref><xref rid="ref15" ref-type="bibr">15</xref><xref rid="ref16" ref-type="bibr">16</xref><xref rid="ref17" ref-type="bibr">17</xref>] abnormal brain-gut interactions,[<xref rid="ref18" ref-type="bibr">18</xref><xref rid="ref19" ref-type="bibr">19</xref><xref rid="ref20" ref-type="bibr">20</xref><xref rid="ref21" ref-type="bibr">21</xref><xref rid="ref22" ref-type="bibr">22</xref><xref rid="ref23" ref-type="bibr">23</xref><xref rid="ref24" ref-type="bibr">24</xref><xref rid="ref25" ref-type="bibr">25</xref><xref rid="ref26" ref-type="bibr">26</xref>] abnormal acid secretion,[<xref rid="ref27" ref-type="bibr">27</xref><xref rid="ref28" ref-type="bibr">28</xref>] genetic susceptibility,[<xref rid="ref29" ref-type="bibr">29</xref><xref rid="ref30" ref-type="bibr">30</xref><xref rid="ref31" ref-type="bibr">31</xref>] imbalanced autonomic nervous system and visceral hypersensitivity.[<xref rid="ref32" ref-type="bibr">32</xref><xref rid="ref33" ref-type="bibr">33</xref><xref rid="ref34" ref-type="bibr">34</xref><xref rid="ref35" ref-type="bibr">35</xref><xref rid="ref36" ref-type="bibr">36</xref><xref rid="ref37" ref-type="bibr">37</xref>] Although the regular pharmacologic treatments for FD include antacids, kinetic-modifying agents, anti-<italic>H. pylori</italic> antibiotics, anxiolytics, and antidepressants, their benefits are limited in many cases and remained unsatisfactory.[<xref rid="ref38" ref-type="bibr">38</xref><xref rid="ref39" ref-type="bibr">39</xref>] That's why the search for optimum treatment is continued, and alternative medicine has gained more and more popularity among the patients and even physicians. It has been estimated by World Health Organization that probably 80% of the population around the world may trust traditional medicine to meet their primary health care needs.[<xref rid="ref40" ref-type="bibr">40</xref>] Unfortunately, there isn&#x02019;t enough satisfactory evidence based on randomized clinical trials to demonstrate the efficacy and safety of the majority of herbal medicines. One of the herbs in the latter group used to treat patients in over 4000-year history of Iranian medicine was <italic>Pimpinella anisum</italic> (Apiaceae).[<xref rid="ref41" ref-type="bibr">41</xref>] Different therapeutic effects have been reported for anise including antioxidant, antifungal,[<xref rid="ref42" ref-type="bibr">42</xref>] antimicrobial,[<xref rid="ref43" ref-type="bibr">43</xref>] analgesic,[<xref rid="ref44" ref-type="bibr">44</xref>] anticonvulsant[<xref rid="ref45" ref-type="bibr">45</xref><xref rid="ref46" ref-type="bibr">46</xref>] and antispastic[<xref rid="ref47" ref-type="bibr">47</xref>] properties. It also has many GI effects. For instance, anise implemented its antiulcer effects by inhibiting gastric mucosal damage.[<xref rid="ref48" ref-type="bibr">48</xref>] The aromatic effects of anise have been effective in the palliation of nausea.[<xref rid="ref49" ref-type="bibr">49</xref>] Its laxative property has been effective in the treatment of constipation.[<xref rid="ref50" ref-type="bibr">50</xref>] The aim of current clinical trial was to assess the effects of anise fruit on patients with PDS.</p></sec><sec sec-type="materials|methods" id="sec1-2"><title>MATERIALS AND METHODS</title><sec id="sec2-1"><title>Study design</title><p>The current study was a double-blind, randomized clinical trial conducted in Isfahan University of Medical Sciences (IUMS). Patients attending Gastroenterology Clinic of the university hospital from August 2013 to March 2014 were evaluated. Totally, 180 patients were visited and assessed. Those who fulfilled the inclusion criteria and signed a written consent form were enrolled in the study. The research protocol was approved by Ethical Committee. The study was registered in Iranian Registry of Clinical Trials (registration number, 2013101214980). Inclusion criteria were age of 18-65 years and diagnosed with PDS according to ROME III criteria. The patients had at least one of the following symptoms occurring several times a week in the past 6 months: The discomfort feeling of postprandial fullness and/or early satiety. Exclusion criteria included pregnancy, breastfeeding, peptic ulcer, gastroesophageal reflux disease, dysphagia, celiac, GI surgery, irritable bowel syndrome, abdominal pain, night diarrhea, greasy or black stool, blood in stool, mental retardation, immune system disorders, major depression, bipolar disorder and psychosomatic disorders, severe recent weight loss, cancer, renal disorders, current use of antibiotics, proton pump inhibitors, H2 blockers, bismuth, metoclopramide, domperidone, lactulose, nonsteroid anti-inflammatory drugs, corticosteroids, herbal medicines and drug abuse. Patients who took &#x0003c;80% of administered medication or had drug intolerance were withdrawn from the study.</p></sec><sec id="sec2-2"><title>Subjects and intervention</title><p>Totally, 107 patients were enrolled in the study [<xref ref-type="fig" rid="F1">Figure 1</xref>]. They were randomized by simple randomization method to blindly receive either anise or placebo for 4 weeks. Intervention group consisted of 47 patients and received anise powder, 3 gafter each meal (3 times/day). According to the Barnes <italic>et al</italic>.,[<xref rid="ref51" ref-type="bibr">51</xref>] administration of up to 20 g/day anise powder is safe. The anise seeds were prepared by Barij Essence Pharmaceutical Company (MashhadArdehal, Iran) as a gift. This plant specimen was kept in their herbarium with number 1697.[<xref rid="ref52" ref-type="bibr">52</xref>] Control group included 60 patients and received placebo powder, 3 g after each meal (3 times/day). The latter included corn starch and were similar to anise package in shape, color, and size. Both powders were prepared in similar packages by Pharmacognosy Department of Isfahan School of Pharmacy at IUMS. One week medications were supplied to the patients at the beginning of the each week for 4 weeks. Both patients and doctors were blind to the treatments.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Consort flowchart of the study</p></caption><graphic xlink:href="JRMS-20-13-g001"/></fig></sec><sec id="sec2-3"><title>Instruments and outcomes</title><p>To evaluate the presence or absence of symptoms of FD, modified ROME III questionnaire,[<xref rid="ref3" ref-type="bibr">3</xref><xref rid="ref53" ref-type="bibr">53</xref>] was used. Its validity and reliability have been tested before.[<xref rid="ref54" ref-type="bibr">54</xref>] The diagnosis of FD was based on the questionnaire filled out individually. To assess the severity of the disorder, FD severity scale was employed.[<xref rid="ref55" ref-type="bibr">55</xref>] 4-item Likert scale (never or rarely, not very unpleasant, very unpleasant but tolerable, and can&#x02019;t tolerate) was employed to answer the questions. Each participant's total score was between 0 and 48. A detailed questionnaire was prepared to record the medication side effects too.</p><p>All patients were followed-up for 12 weeks. The primary and secondary endpoints were the mean score of severity of FD and the frequency distribution of patients with various severities across the study period, respectively. Assessments were carried out at baseline and at the end of weeks 2, 4 and 12.</p></sec><sec id="sec2-4"><title>Statistical analysis</title><p>Intention to treat analysis was used to avoid the bias associated with nonrandom loss of patients. Characteristics of the two groups were compared before and after intervention using Mann-Whitney U and Kruskal-Wallis tests for nonparametric variables and Student's <italic>t</italic>-test for parametric variables. The changes from the baseline to the end of study period within each group were tested using Friedman test and related samples Friedman's two-way analysis of variance by ranks test. <italic>P</italic> &#x0003c; 0.05 were considered significant. Statistical Package for Social Sciences (SPSS Inc., Chicago, IL, USA), version 17 for Windows was used to conduct statistical analysis.</p></sec></sec><sec sec-type="results" id="sec1-3"><title>RESULTS</title><p>Totally, 107 patients were enrolled in the study. Totally, 32 (53.3%) and 21 (44.7%) females were included in the control and intervention groups, respectively. The difference was not significant (<italic>P</italic> = 0.3). The mean (standard deviation [SD]) age of patients in the control group was 41 (11.7) and in the intervention group was 45.5 (15.5) years (<italic>P</italic> = 0.1). Totally, 34 (56.7%) and 32 (68%) patients had body mass index &#x02264;25 in the control and intervention groups, respectively (<italic>P</italic> = 0.4). Totally, 47 (78.3%) patients in the control group and 36 (76.6%) patients in the intervention group never smoked cigarettes (<italic>P</italic> = 0.9). Totally, 58 (96.7%) and 43 (91%) patients didn&#x02019;t drink coffee in the control and intervention groups, respectively (<italic>P</italic> = 0.1). Four patients were withdrawn from the study in each group [<xref ref-type="fig" rid="F1">Figure 1</xref>]. No serious medication side effect was reported in anise group.</p><p>Mean (SD) scores of 16 questions of FD severity scale in the two groups across the study period are shown in <xref ref-type="table" rid="T1">Table 1</xref>. Among all symptoms, epigastric fullness showed the highest severity and nausea demonstrated the lowest severity in both groups before the intervention [<xref ref-type="table" rid="T1">Table 1</xref>]. In other words, about 90% of patients had epigastric fullness whereas &#x02264;5% suffered from nausea in both groups at baseline. The baseline mean scores of different FD symptoms were not significantly different between the two groups. After intervention, all symptoms were significantly different between the two groups at weeks 4 and 12, but retching, nausea and vomiting. Similarly, mean total scores of FD severity scale were not significantly different between the two groups before the intervention. But, they were significantly different between the two groups at weeks 2, 4 and 12 [<xref ref-type="table" rid="T1">Table 1</xref>].</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Comparison of mean (SD) scores of severity of FD within and between the two groups across the study period</p></caption><graphic xlink:href="JRMS-20-13-g002"/></table-wrap><p>Mean severity scores of epigastric fullness, epigastric discomfort, epigastric burning/pain, early satiety, bloating, belching, and loss of appetite decreased significantly within anise group after intervention whereas only epigastric discomfort showed similar pattern within placebo group. On the other hand, mean severity scores of epigastric pain, epigastric fullness and belching increased significantly within the placebo group after intervention whereas no symptom revealed such an increasing score pattern within anise group [<xref ref-type="table" rid="T1">Table 1</xref>].</p><p>Distributions of the patients in different scales of severity of FD symptoms across the study period are demonstrated in <xref ref-type="table" rid="T2">Table 2</xref>. Similar to the mean severity scores, the distributions of patients before intervention were not significantly different between the two groups [<xref ref-type="table" rid="T2">Table 2</xref>]. Furthermore, the patterns of significance and nonsignificance of distributions of patients within each group and between the two groups were similar to those of the severity scores.</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Distributions of the patients according to various degrees of severity of FD and comparison of distributions within and between the two groups across the study period</p></caption><graphic xlink:href="JRMS-20-13-g003"/></table-wrap></sec><sec sec-type="discussion" id="sec1-4"><title>DISCUSSION</title><p>The current study demonstrated that anise was effective in the treatment of postpartum depression (PPD). Since the pathophysiology of FD is multifactorial and since anise has broad spectrum of pharmacological effects on GI, nervous, muscular and immune systems, it is not a surprise to see significant improvements of symptoms in patients with FD. The spasmolytic feature[<xref rid="ref50" ref-type="bibr">50</xref>] of anise and its pain relieving character may explain the improvement of postprandial pain and epigastric discomfort. Antimicrobial effects[<xref rid="ref43" ref-type="bibr">43</xref>] of anise against most bacteria may decrease or inhibit the activities of <italic>H. pylori</italic> in these patients. Inhibitory effects of anise on gastric mucosal damage[<xref rid="ref48" ref-type="bibr">48</xref>] may decrease the micro-inflammation of FD. The most important constituents of aniseeds essential oils responsible for the reported effects are trans-anethole, estragole, &#x003b3;-hymachalen, p-anisaldehyde, and methyl chavicol.[<xref rid="ref56" ref-type="bibr">56</xref>]</p><p>Some other herbs have also been investigated to find out their effectiveness on FD treatment with various results. The most famous ones were Iberogas (a herbal combination preparation, STW 5) which improved the symptoms of FD in 52-68% of cases and peppermint which was effective in 67-97% of patients.[<xref rid="ref57" ref-type="bibr">57</xref>] Some of them have also been recognized to relieve bloating and intestinal gas. They are called carminatives. Anise, peppermint, and cinnamon are the prototypes of these herbs but few clinical trials have been carried out to show the evidence.[<xref rid="ref58" ref-type="bibr">58</xref>] This was the first randomized clinical trial assessing the therapeutic effects of anise on patients with FD. But, this study had the following limitations. First, it was conducted in a single center. Thus, the study population was homogenous which limited the external validity of the results. Second, the sample size was small, and the follow-up period was relatively short. It is suggested to include larger numbers of patients with longer periods of follow-up in multiple centers in the future investigations.</p></sec><sec sec-type="conclusions" id="sec1-5"><title>CONCLUSIONS</title><p>Anise was effective and tolerable in the relieving the symptoms of PPD. These effects were observed even 8 weeks after discontinuation of anise administration.</p></sec><sec id="sec1-6"><title>AUTHOR'S CONTRIBUTION</title><p>MM was the principal investigator of the study. MT participated in preparing the design of the study and collecting the data. PA participated in preparing the design of the study, revisited the manuscript and critically evaluated the intellectual contents. AF conducted the analysis of data. AG participated in preparing the final draft of the manuscript, revisited the manuscript and critically evaluated the intellectual contents. MK coordinated in study design and data collection. SAG participated in the preparation of the final draft of the manuscript, revisited the manuscript and critically evaluated the intellectual contents. MB participated in data collection and preparation of the final draft of the manuscript, revisited the manuscript and critically evaluated the intellectual contents.</p></sec></body><back><ack><title>ACKNOWLEDGMENT</title><p>The authors would like to thank Dr. Maryam Mohammadi Masoodi, who assisted us in the execution of the study.</p></ack><fn-group><fn fn-type="supported-by"><p><bold>Source of Support:</bold> Nil</p></fn><fn fn-type="conflict"><p><bold>Conflict of Interest:</bold> No conflict of interests.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>L</given-names></name><name><surname>Toner</surname><given-names>BB</given-names></name><name><surname>Fukudo</surname><given-names>S</given-names></name><name><surname>Guthrie</surname><given-names>E</given-names></name><name><surname>Locke</surname><given-names>GR</given-names></name><name><surname>Norton</surname><given-names>NJ</given-names></name><etal/></person-group><article-title>Gender, age, society, culture, and the patient's perspective in the functional gastrointestinal disorders</article-title><source>Gastroenterology</source><year>2006</year><volume>130</volume><fpage>1435</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">16678557</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>MK</given-names></name><name><surname>Liu</surname><given-names>SZ</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name></person-group><article-title>Immunoinflammation and functional gastrointestinal disorders</article-title><source>Saudi J Gastroenterol</source><year>2012</year><volume>18</volume><fpage>225</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">22824763</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drossman</surname><given-names>DA</given-names></name><name><surname>Dumitrascu</surname><given-names>DL</given-names></name></person-group><article-title>Rome III: New standard for functional gastrointestinal disorders</article-title><source>J Gastrointestin Liver Dis</source><year>2006</year><volume>15</volume><fpage>237</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">17013448</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drossman</surname><given-names>DA</given-names></name><name><surname>Corazziari</surname><given-names>E</given-names></name><name><surname>Delvaux</surname><given-names>M</given-names></name><name><surname>Spiller</surname><given-names>R</given-names></name><name><surname>Talley</surname><given-names>NJ</given-names></name><name><surname>Thompson</surname><given-names>WG</given-names></name></person-group><article-title>Appendix B: Rome III diagnostic criteria for functional gastrointestinal disorders</article-title><source>Rev Gastroenterol Mex</source><year>2010</year><volume>75</volume><fpage>511</fpage><lpage>6</lpage></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cogliandro</surname><given-names>RF</given-names></name><name><surname>Antonucci</surname><given-names>A</given-names></name><name><surname>De Giorgio</surname><given-names>R</given-names></name><name><surname>Barbara</surname><given-names>G</given-names></name><name><surname>Cremon</surname><given-names>C</given-names></name><name><surname>Cogliandro</surname><given-names>L</given-names></name><etal/></person-group><article-title>Patient-reported outcomes and gut dysmotility in functional gastrointestinal disorders</article-title><source>Neurogastroenterol Motil</source><year>2011</year><volume>23</volume><fpage>1084</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">21917083</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mizuta</surname><given-names>Y</given-names></name><name><surname>Shikuwa</surname><given-names>S</given-names></name><name><surname>Isomoto</surname><given-names>H</given-names></name><name><surname>Mishima</surname><given-names>R</given-names></name><name><surname>Akazawa</surname><given-names>Y</given-names></name><name><surname>Masuda</surname><given-names>J</given-names></name><etal/></person-group><article-title>Recent insights into digestive motility in functional dyspepsia</article-title><source>J Gastroenterol</source><year>2006</year><volume>41</volume><fpage>1025</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">17160514</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lorena</surname><given-names>SL</given-names></name><name><surname>de Souza Almeida</surname><given-names>JR</given-names></name><name><surname>Mesquita</surname><given-names>MA</given-names></name></person-group><article-title>Orocecal transit time in patients with functional dyspepsia</article-title><source>J Clin Gastroenterol</source><year>2002</year><volume>35</volume><fpage>21</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">12080221</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bektas</surname><given-names>M</given-names></name><name><surname>Soykan</surname><given-names>I</given-names></name><name><surname>Altan</surname><given-names>M</given-names></name><name><surname>Alkan</surname><given-names>M</given-names></name><name><surname>Ozden</surname><given-names>A</given-names></name></person-group><article-title>The effect of <italic>Helicobacter pylori</italic> eradication on dyspeptic symptoms, acid reflux and quality of life in patients with functional dyspepsia</article-title><source>Eur J Intern Med</source><year>2009</year><volume>20</volume><fpage>419</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">19524187</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>H</given-names></name><name><surname>Masaoka</surname><given-names>T</given-names></name><name><surname>Sakai</surname><given-names>G</given-names></name><name><surname>Ishii</surname><given-names>H</given-names></name><name><surname>Hibi</surname><given-names>T</given-names></name></person-group><article-title>Improvement of gastrointestinal quality of life scores in cases of <italic>Helicobacter pylori</italic>-positive functional dyspepsia after successful eradication therapy</article-title><source>J Gastroenterol Hepatol</source><year>2005</year><volume>20</volume><fpage>1652</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">16246181</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ladron de</surname><given-names>GL</given-names></name><name><surname>Pena-Alfaro</surname><given-names>NG</given-names></name><name><surname>Padilla</surname><given-names>L</given-names></name><name><surname>Lichtinger</surname><given-names>A</given-names></name><name><surname>Figueroa</surname><given-names>S</given-names></name><name><surname>Shapiro</surname><given-names>I</given-names></name><etal/></person-group><article-title>Evaluation of the symptomatology and quality of life in functional dyspepsia before and after <italic>Helicobacter pylori</italic> eradication treatment</article-title><source>Rev Gastroenterol Mex</source><year>2004</year><volume>69</volume><fpage>203</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">15765971</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alekseenko</surname><given-names>SA</given-names></name><name><surname>Krapivnaia</surname><given-names>OV</given-names></name><name><surname>Kamalova</surname><given-names>OK</given-names></name><name><surname>Vasiaev</surname><given-names>VI</given-names></name><name><surname>Pyrkh</surname><given-names>AV</given-names></name></person-group><article-title>Dynamics of clinical symptoms, indices of quality of life, and the state of motor function of the esophagus and rectum in patients with functional dyspepsia and irritable bowel syndrome after <italic>Helicobacter pylori</italic> eradication</article-title><source>Eksp Klin Gastroenterol</source><year>2003</year><volume>115</volume><fpage>54</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">14653240</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>YC</given-names></name><name><surname>Wang</surname><given-names>WM</given-names></name><name><surname>Wang</surname><given-names>SY</given-names></name><name><surname>Lu</surname><given-names>SN</given-names></name><name><surname>Chen</surname><given-names>LT</given-names></name><name><surname>Wu</surname><given-names>DC</given-names></name><etal/></person-group><article-title>The association between <italic>Helicobacter pylori</italic> infection and functional dyspepsia in patients with irritable bowel syndrome</article-title><source>Am J Gastroenterol</source><year>2000</year><volume>95</volume><fpage>1900</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">10950033</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayer</surname><given-names>EA</given-names></name><name><surname>Collins</surname><given-names>SM</given-names></name></person-group><article-title>Evolving pathophysiologic models of functional gastrointestinal disorders</article-title><source>Gastroenterology</source><year>2002</year><volume>122</volume><fpage>2032</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">12055608</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mearin</surname><given-names>F</given-names></name><name><surname>Balboa</surname><given-names>A</given-names></name></person-group><article-title>Post-infectious functional gastrointestinal disorders: From the acute episode to chronicity</article-title><source>Gastroenterol Hepatol</source><year>2011</year><volume>34</volume><fpage>415</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">21641686</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mearin</surname><given-names>F</given-names></name><name><surname>Perell&#x000f3;</surname><given-names>A</given-names></name><name><surname>Balboa</surname><given-names>A</given-names></name><name><surname>Perona</surname><given-names>M</given-names></name><name><surname>Sans</surname><given-names>M</given-names></name><name><surname>Salas</surname><given-names>A</given-names></name><etal/></person-group><article-title>Pathogenic mechanisms of postinfectious functional gastrointestinal disorders: Results 3 years after gastroenteritis</article-title><source>Scand J Gastroenterol</source><year>2009</year><volume>44</volume><fpage>1173</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">19711225</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santos</surname><given-names>J</given-names></name><name><surname>Alonso</surname><given-names>C</given-names></name><name><surname>Guilarte</surname><given-names>M</given-names></name><name><surname>Vicario</surname><given-names>M</given-names></name><name><surname>Malagelada</surname><given-names>JR</given-names></name></person-group><article-title>Targeting mast cells in the treatment of functional gastrointestinal disorders</article-title><source>Curr Opin Pharmacol</source><year>2006</year><volume>6</volume><fpage>541</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">16956793</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schurman</surname><given-names>JV</given-names></name><name><surname>Singh</surname><given-names>M</given-names></name><name><surname>Singh</surname><given-names>V</given-names></name><name><surname>Neilan</surname><given-names>N</given-names></name><name><surname>Friesen</surname><given-names>CA</given-names></name></person-group><article-title>Symptoms and subtypes in pediatric functional dyspepsia: Relation to mucosal inflammation and psychological functioning</article-title><source>J Pediatr Gastroenterol Nutr</source><year>2010</year><volume>51</volume><fpage>298</fpage><lpage>303</lpage><pub-id pub-id-type="pmid">20479684</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>G</given-names></name><name><surname>Qin</surname><given-names>W</given-names></name><name><surname>Zeng</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>von Deneen</surname><given-names>KM</given-names></name><etal/></person-group><article-title>White-matter microstructural changes in functional dyspepsia: A diffusion tensor imaging study</article-title><source>Am J Gastroenterol</source><year>2013</year><volume>108</volume><fpage>260</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">23229422</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koloski</surname><given-names>NA</given-names></name><name><surname>Jones</surname><given-names>M</given-names></name><name><surname>Kalantar</surname><given-names>J</given-names></name><name><surname>Weltman</surname><given-names>M</given-names></name><name><surname>Zaguirre</surname><given-names>J</given-names></name><name><surname>Talley</surname><given-names>NJ</given-names></name></person-group><article-title>The brain - gut pathway in functional gastrointestinal disorders is bidirectional: A 12-year prospective population-based study</article-title><source>Gut</source><year>2012</year><volume>61</volume><fpage>1284</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">22234979</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koloski</surname><given-names>NA</given-names></name><name><surname>Jones</surname><given-names>M</given-names></name><name><surname>Talley</surname><given-names>NJ</given-names></name></person-group><article-title>Investigating the directionality of the brain-gut mechanism in functional gastrointestinal disorders</article-title><source>Gut</source><year>2012</year><volume>61</volume><fpage>1776</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">23293789</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>ML</given-names></name><name><surname>Liang</surname><given-names>FR</given-names></name><name><surname>Zeng</surname><given-names>F</given-names></name><name><surname>Tang</surname><given-names>Y</given-names></name><name><surname>Lan</surname><given-names>L</given-names></name><name><surname>Song</surname><given-names>WZ</given-names></name></person-group><article-title>Cortical-limbic regions modulate depression and anxiety factors in functional dyspepsia: A PET-CT study</article-title><source>Ann Nucl Med</source><year>2012</year><volume>26</volume><fpage>35</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">21953211</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whitehouse</surname><given-names>HJ</given-names></name><name><surname>Ford</surname><given-names>AC</given-names></name></person-group><article-title>Direction of the brain &#x02013; gut pathway in functional gastrointestinal disorders</article-title><source>Gut</source><year>2012</year><volume>61</volume><fpage>1368</fpage><pub-id pub-id-type="pmid">22387527</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tillisch</surname><given-names>K</given-names></name><name><surname>Labus</surname><given-names>JS</given-names></name></person-group><article-title>Advances in imaging the brain-gut axis: Functional gastrointestinal disorders</article-title><source>Gastroenterology</source><year>2011</year><volume>140</volume><fpage>407</fpage><lpage>411.e1</lpage><pub-id pub-id-type="pmid">21167161</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>B&#x000f6;hmelt</surname><given-names>AH</given-names></name><name><surname>Nater</surname><given-names>UM</given-names></name><name><surname>Franke</surname><given-names>S</given-names></name><name><surname>Hellhammer</surname><given-names>DH</given-names></name><name><surname>Ehlert</surname><given-names>U</given-names></name></person-group><article-title>Basal and stimulated hypothalamic-pituitary-adrenal axis activity in patients with functional gastrointestinal disorders and healthy controls</article-title><source>Psychosom Med</source><year>2005</year><volume>67</volume><fpage>288</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">15784796</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hobson</surname><given-names>AR</given-names></name><name><surname>Aziz</surname><given-names>Q</given-names></name></person-group><article-title>Brain imaging and functional gastrointestinal disorders: Has it helped our understanding?</article-title><source>Gut</source><year>2004</year><volume>53</volume><fpage>1198</fpage><lpage>206</lpage><pub-id pub-id-type="pmid">15247191</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clouse</surname><given-names>RE</given-names></name></person-group><article-title>Pharmacotherapy of altered brain-gut interactions in functional gastrointestinal disorders</article-title><source>J Pediatr Gastroenterol Nutr</source><year>1997</year><volume>25</volume><issue>Suppl 1</issue><fpage>S18</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">9285856</pub-id></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collingwood</surname><given-names>S</given-names></name><name><surname>Witherington</surname><given-names>J</given-names></name></person-group><article-title>Therapeutic approaches towards the treatment of gastroinstestinal disorders</article-title><source>Drug News Perspect</source><year>2007</year><volume>20</volume><fpage>139</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">17440638</pub-id></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farr&#x000e9;</surname><given-names>R</given-names></name><name><surname>Tack</surname><given-names>J</given-names></name></person-group><article-title>Food and symptom generation in functional gastrointestinal disorders: Physiological aspects</article-title><source>Am J Gastroenterol</source><year>2013</year><volume>108</volume><fpage>698</fpage><lpage>706</lpage><pub-id pub-id-type="pmid">23458851</pub-id></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adam</surname><given-names>B</given-names></name><name><surname>Liebregts</surname><given-names>T</given-names></name><name><surname>Holtmann</surname><given-names>G</given-names></name></person-group><article-title>Mechanisms of disease: Genetics of functional gastrointestinal disorders &#x02013; searching the genes that matter</article-title><source>Nat Clin Pract Gastroenterol Hepatol</source><year>2007</year><volume>4</volume><fpage>102</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">17268545</pub-id></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camilleri</surname><given-names>M</given-names></name><name><surname>Carlson</surname><given-names>P</given-names></name><name><surname>Zinsmeister</surname><given-names>AR</given-names></name><name><surname>McKinzie</surname><given-names>S</given-names></name><name><surname>Busciglio</surname><given-names>I</given-names></name><name><surname>Burton</surname><given-names>D</given-names></name><etal/></person-group><article-title>Neuropeptide S receptor induces neuropeptide expression and associates with intermediate phenotypes of functional gastrointestinal disorders</article-title><source>Gastroenterology</source><year>2010</year><volume>138</volume><fpage>98</fpage><lpage>107.e4</lpage><pub-id pub-id-type="pmid">19732772</pub-id></element-citation></ref><ref id="ref31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holtmann</surname><given-names>G</given-names></name><name><surname>Liebregts</surname><given-names>T</given-names></name><name><surname>Siffert</surname><given-names>W</given-names></name></person-group><article-title>Molecular basis of functional gastrointestinal disorders</article-title><source>Best Pract Res Clin Gastroenterol</source><year>2004</year><volume>18</volume><fpage>633</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">15324704</pub-id></element-citation></ref><ref id="ref32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castilloux</surname><given-names>J</given-names></name><name><surname>Noble</surname><given-names>A</given-names></name><name><surname>Faure</surname><given-names>C</given-names></name></person-group><article-title>Is visceral hypersensitivity correlated with symptom severity in children with functional gastrointestinal disorders?</article-title><source>J Pediatr Gastroenterol Nutr</source><year>2008</year><volume>46</volume><fpage>272</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">18376243</pub-id></element-citation></ref><ref id="ref33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faure</surname><given-names>C</given-names></name><name><surname>Gigu&#x000e8;re</surname><given-names>L</given-names></name></person-group><article-title>Functional gastrointestinal disorders and visceral hypersensitivity in children and adolescents suffering from Crohn's disease</article-title><source>Inflamm Bowel Dis</source><year>2008</year><volume>14</volume><fpage>1569</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">18521915</pub-id></element-citation></ref><ref id="ref34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faure</surname><given-names>C</given-names></name><name><surname>Wieckowska</surname><given-names>A</given-names></name></person-group><article-title>Somatic referral of visceral sensations and rectal sensory threshold for pain in children with functional gastrointestinal disorders</article-title><source>J Pediatr</source><year>2007</year><volume>150</volume><fpage>66</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">17188617</pub-id></element-citation></ref><ref id="ref35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malagelada</surname><given-names>JR</given-names></name></person-group><article-title>Sensation and gas dynamics in functional gastrointestinal disorders</article-title><source>Gut</source><year>2002</year><volume>51</volume><issue>Suppl 1</issue><fpage>i72</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">12077071</pub-id></element-citation></ref><ref id="ref36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>M&#x000f6;nnikes</surname><given-names>H</given-names></name><name><surname>Tebbe</surname><given-names>JJ</given-names></name><name><surname>Hildebrandt</surname><given-names>M</given-names></name><name><surname>Arck</surname><given-names>P</given-names></name><name><surname>Osmanoglou</surname><given-names>E</given-names></name><name><surname>Rose</surname><given-names>M</given-names></name><etal/></person-group><article-title>Role of stress in functional gastrointestinal disorders. Evidence for stress-induced alterations in gastrointestinal motility and sensitivity</article-title><source>Dig Dis</source><year>2001</year><volume>19</volume><fpage>201</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">11752838</pub-id></element-citation></ref><ref id="ref37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quigley</surname><given-names>EM</given-names></name></person-group><article-title>Disturbances of motility and visceral hypersensitivity in irritable bowel syndrome: Biological markers or epiphenomenon</article-title><source>Gastroenterol Clin North Am</source><year>2005</year><volume>34</volume><fpage>221</fpage><lpage>33</lpage><comment>vi</comment><pub-id pub-id-type="pmid">15862931</pub-id></element-citation></ref><ref id="ref38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zwolinska-Wcislo</surname><given-names>M</given-names></name><name><surname>Galicka-Latala</surname><given-names>D</given-names></name></person-group><article-title>Epidemiology, classification and management of functional dyspepsia</article-title><source>Przegl Lek</source><year>2008</year><volume>65</volume><fpage>867</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">19441680</pub-id></element-citation></ref><ref id="ref39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>JC</given-names></name></person-group><article-title>Psychological co-morbidity in functional gastrointestinal disorders: Epidemiology, mechanisms and management</article-title><source>J Neurogastroenterol Motil</source><year>2012</year><volume>18</volume><fpage>13</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">22323984</pub-id></element-citation></ref><ref id="ref40"><label>40</label><element-citation publication-type="book"><article-title>World Health Organization. The World Health Report, Mental Health: New Understanding New Hope</article-title><year>2001</year><publisher-loc>Geneva, Switzerland</publisher-loc><publisher-name>World Health Organization</publisher-name></element-citation></ref><ref id="ref41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdollahi</surname><given-names>Fard M</given-names></name><name><surname>Shojaii</surname><given-names>A</given-names></name></person-group><article-title>Efficacy of Iranian traditional medicine in the treatment of epilepsy</article-title><source>Biomed Res Int 2013</source><year>2013</year><comment>692751</comment></element-citation></ref><ref id="ref42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kosalec</surname><given-names>I</given-names></name><name><surname>Pepeljnjak</surname><given-names>S</given-names></name><name><surname>Kustrak</surname><given-names>D</given-names></name></person-group><article-title>Antifungal activity of fluid extract and essential oil from anise fruits (<italic>Pimpinella anisum</italic> L. Apiaceae)</article-title><source>Acta Pharm</source><year>2005</year><volume>55</volume><fpage>377</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">16375827</pub-id></element-citation></ref><ref id="ref43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaudhry</surname><given-names>NM</given-names></name><name><surname>Tariq</surname><given-names>P</given-names></name></person-group><article-title>Bactericidal activity of black pepper, bay leaf, aniseed and coriander against oral isolates</article-title><source>Pak J Pharm Sci</source><year>2006</year><volume>19</volume><fpage>214</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16935829</pub-id></element-citation></ref><ref id="ref44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tas</surname><given-names>A</given-names></name></person-group><article-title>Analgesic effect of <italic>Pimpinella anisum</italic> L. essential oil extract in mice</article-title><source>Indian Vet J</source><year>2009</year><volume>86</volume><fpage>145</fpage><lpage>7</lpage></element-citation></ref><ref id="ref45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karimzadeh</surname><given-names>F</given-names></name><name><surname>Hosseini</surname><given-names>M</given-names></name><name><surname>Mangeng</surname><given-names>D</given-names></name><name><surname>Alavi</surname><given-names>H</given-names></name><name><surname>Hassanzadeh</surname><given-names>GR</given-names></name><name><surname>Bayat</surname><given-names>M</given-names></name><etal/></person-group><article-title>Anticonvulsant and neuroprotective effects of <italic>Pimpinella anisum</italic> in rat brain</article-title><source>BMC Complement Altern Med</source><year>2012</year><volume>12</volume><fpage>76</fpage><pub-id pub-id-type="pmid">22709243</pub-id></element-citation></ref><ref id="ref46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pourgholami</surname><given-names>MH</given-names></name><name><surname>Majzoob</surname><given-names>S</given-names></name><name><surname>Javadi</surname><given-names>M</given-names></name><name><surname>Kamalinejad</surname><given-names>M</given-names></name><name><surname>Fanaee</surname><given-names>GH</given-names></name><name><surname>Sayyah</surname><given-names>M</given-names></name></person-group><article-title>The fruit essential oil of <italic>Pimpinella anisum</italic> exerts anticonvulsant effects in mice</article-title><source>J Ethnopharmacol</source><year>1999</year><volume>66</volume><fpage>211</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">10433480</pub-id></element-citation></ref><ref id="ref47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tirapelli</surname><given-names>CR</given-names></name><name><surname>de Andrade</surname><given-names>CR</given-names></name><name><surname>Cassano</surname><given-names>AO</given-names></name><name><surname>De Souza</surname><given-names>FA</given-names></name><name><surname>Ambrosio</surname><given-names>SR</given-names></name><name><surname>da Costa</surname><given-names>FB</given-names></name><etal/></person-group><article-title>Antispasmodic and relaxant effects of the hidroalcoholic extract of <italic>Pimpinella anisum</italic> (Apiaceae) on rat anococcygeus smooth muscle</article-title><source>J Ethnopharmacol</source><year>2007</year><volume>110</volume><fpage>23</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">17027208</pub-id></element-citation></ref><ref id="ref48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al Mofleh</surname><given-names>IA</given-names></name><name><surname>Alhaider</surname><given-names>AA</given-names></name><name><surname>Mossa</surname><given-names>JS</given-names></name><name><surname>Al-Soohaibani</surname><given-names>MO</given-names></name><name><surname>Rafatullah</surname><given-names>S</given-names></name></person-group><article-title>Aqueous suspension of anise &#x0201c;<italic>Pimpinella anisum</italic>&#x0201d; protects rats against chemically induced gastric ulcers</article-title><source>World J Gastroenterol</source><year>2007</year><volume>13</volume><fpage>1112</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">17373749</pub-id></element-citation></ref><ref id="ref49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilligan</surname><given-names>NP</given-names></name></person-group><article-title>The palliation of nausea in hospice and palliative care patients with essential oils of <italic>Pimpinella anisum</italic> (aniseed), <italic>Foeniculum vulgare</italic> var. dulce (sweet fennel), <italic>Anthemis nobilis</italic> (Roman chamomile) and Mentha x piperita (peppermint)</article-title><source>Int J Aromather</source><year>2005</year><volume>15</volume><fpage>163</fpage><lpage>7</lpage></element-citation></ref><ref id="ref50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Picon</surname><given-names>PD</given-names></name><name><surname>Picon</surname><given-names>RV</given-names></name><name><surname>Costa</surname><given-names>AF</given-names></name><name><surname>Sander</surname><given-names>GB</given-names></name><name><surname>Amaral</surname><given-names>KM</given-names></name><name><surname>Aboy</surname><given-names>AL</given-names></name><etal/></person-group><article-title>Randomized clinical trial of a phytotherapic compound containing <italic>Pimpinella anisum</italic>, <italic>Foeniculum vulgare, Sambucus nigra</italic>, and <italic>Cassia augustifolia</italic> for chronic constipation</article-title><source>BMC Complement Altern Med</source><year>2010</year><volume>10</volume><fpage>17</fpage><pub-id pub-id-type="pmid">20433751</pub-id></element-citation></ref><ref id="ref51"><label>51</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Barnes</surname><given-names>J</given-names></name><name><surname>Anderson</surname><given-names>LA</given-names></name><name><surname>Phillipson</surname><given-names>JD</given-names></name></person-group><article-title>Aniseed</article-title><source>Herbal Medicine: A Guide for Health Care Professionals</source><year>2007</year><edition>3rd ed</edition><publisher-loc>IL, USA</publisher-loc><publisher-name>Pharmaceutical Press</publisher-name></element-citation></ref><ref id="ref52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kazemi</surname><given-names>M</given-names></name><name><surname>Eshraghi</surname><given-names>A</given-names></name><name><surname>Yegdaneh</surname><given-names>A</given-names></name><name><surname>Ghannadi</surname><given-names>A</given-names></name></person-group><article-title>&#x0201c;Clinical pharmacognosy&#x0201d;- A new interesting era of pharmacy in the third millennium</article-title><source>Daru</source><year>2012</year><volume>20</volume><fpage>18</fpage><pub-id pub-id-type="pmid">23351785</pub-id></element-citation></ref><ref id="ref53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drossman</surname><given-names>DA</given-names></name></person-group><article-title>The functional gastrointestinal disorders and the Rome III process</article-title><source>Gastroenterology</source><year>2006</year><volume>130</volume><fpage>1377</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">16678553</pub-id></element-citation></ref><ref id="ref54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sorouri</surname><given-names>M</given-names></name><name><surname>Pourhoseingholi</surname><given-names>MA</given-names></name><name><surname>Vahedi</surname><given-names>M</given-names></name><name><surname>Safaee</surname><given-names>A</given-names></name><name><surname>Moghimi-Dehkordi</surname><given-names>B</given-names></name><name><surname>Pourhoseingholi</surname><given-names>A</given-names></name><etal/></person-group><article-title>Functional bowel disorders in Iranian population using Rome III criteria</article-title><source>Saudi J Gastroenterol</source><year>2010</year><volume>16</volume><fpage>154</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">20616409</pub-id></element-citation></ref><ref id="ref55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adibi</surname><given-names>P</given-names></name><name><surname>Keshteli</surname><given-names>AH</given-names></name><name><surname>Esmaillzadeh</surname><given-names>A</given-names></name><name><surname>Afshar</surname><given-names>H</given-names></name><name><surname>Roohafza</surname><given-names>H</given-names></name><name><surname>Bagherian-Sararoudi</surname><given-names>R</given-names></name><etal/></person-group><article-title>The study on the epidemiology of psychological, alimentary health and nutrition (SEPAHAN): Overview of methodology</article-title><source>J Res Med Sci</source><year>2012</year><volume>17</volume><issue>Spec 2</issue><fpage>S291</fpage><lpage>S297</lpage></element-citation></ref><ref id="ref56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shojaii</surname><given-names>A</given-names></name><name><surname>Abdollahi</surname><given-names>Fard M</given-names></name></person-group><article-title>Review of pharmacological properties and chemical constituents of <italic>Pimpinella anisum</italic></article-title><source>ISRN Pharm 2012</source><year>2012</year><comment>510795</comment></element-citation></ref><ref id="ref57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>Coon J</given-names></name><name><surname>Ernst</surname><given-names>E</given-names></name></person-group><article-title>Systematic review: Herbal medicinal products for non-ulcer dyspepsia</article-title><source>Aliment Pharmacol Ther</source><year>2002</year><volume>16</volume><fpage>1689</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">12269960</pub-id></element-citation></ref><ref id="ref58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Low Dog</surname><given-names>T</given-names></name></person-group><article-title>A reason to season: The therapeutic benefits of spices and culinary herbs</article-title><source>Explore (NY)</source><year>2006</year><volume>2</volume><fpage>446</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">16979110</pub-id></element-citation></ref></ref-list></back></article>